A Phase IIB Study of Neoadjuvant Enzalutamide (ZT) Regimen Therapy in Combination With Weekly Paclitaxel for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer

Trial Profile

A Phase IIB Study of Neoadjuvant Enzalutamide (ZT) Regimen Therapy in Combination With Weekly Paclitaxel for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2017

At a glance

  • Drugs Enzalutamide (Primary) ; Paclitaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Sep 2016 Planned primary completion date changed from 1 Dec 2020 to 1 Sep 2020.
    • 22 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 18 Aug 2016 Planned primary completion date changed from 1 Jun 2020 to 1 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top